Propanc Biopharma Inc (PPCB)

[Alziyuguru]

Today midday dip was a “GIFT” buying opportunity. PPCB should be on its way back to this year’s highs of $0.77 a share.
Propanc Biopharma Inc (PPCB) stock has bounced back to life on news the company has entered a national phase on two key patents for cancer treatment. Also PPCB benefit from the "Right to Try Act"President Trump signed aimed at allowing terminally ill patients a right to try a drug that is not currently FDA approved. This is a really major development for innovative biotech like PPCB.

Price action points to further movements on the upside as the upward momentum continues to gather pace, the stock should be on its way back to this year’s highs of $0.77 a share.